1069. Meta-analyses of Microarray Data Reveals Interferon Signaling is Top Canonical Pathway in HIV
Session: Poster Abstract Session: HIV: Basic Science and Pathogenesis
Friday, October 9, 2015
Room: Poster Hall
Posters
  • HIV Stargeo.pdf (982.2 kB)
  • Background: Although many different studies have profiled gene expression for humans in response to HIV, most have been performed by only a single group or laboratory and suffer from a lack of generalizability of their results.

    Methods: In this work, we define robust gene signatures or specific patterns of gene expression for the human response to HIV phenotypes through two different meta-analyses. The first is a disease signature found in PBMCs for HIV versus control patients that consists of 24 series. The second is a signature in PBMCs for patients with an elite response to HIV versus patients with a standard response that consists of 5 series.

    Results: We have found interferon signaling to be the top canonical pathway with IFNA2 to be the top upstream regulator in HIV. We have also found that Myd88 is upregulated in HIV, but is not as upregulated in patients with an elite response. Related to this, we’ve found that TLRs 1, 2, 3, and 8 are all upregulated while TLRs 9 and 10 are downregulated in HIV and TLR5 and TLR7 are both expressed less in elite responders.

    Conclusion: Interferon has long been suspected as a potential treatment for HIV-infected patients, and our work support this hypothesis. The robust gene signatures we report here are a first step towards novel transitional opportunities for better biomarkers and drugs for the disease.

    Osama El-Sayed, BS1, Omar Hadied, BS2, Jihad Al-Jabban, BS3, Bilal Zaidi, BS4, Shuaib Raza, BS5, James Pan, BA6, Tej Azad, BA6, Imad Al-Jabban, BS3 and Dexter Hadley, MD/PhD7, (1)College of Medicine, University of Illinois at Chicago, Chicago, IL, (2)Wayne State University, Detroit, MI, (3)Department of Immunology, Harvard University, Boston, MA, (4)University of Michigan, Ann Arbor, MI, (5)Yale School of Medicine, Yale University, New Haven, CT, (6)Stanford University, Stanford, CA, (7)University of California San Francisco, San Francisco, CA

    Disclosures:

    O. El-Sayed, None

    O. Hadied, None

    J. Al-Jabban, None

    B. Zaidi, None

    S. Raza, None

    J. Pan, None

    T. Azad, None

    I. Al-Jabban, None

    D. Hadley, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.